Breaking Finance News

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has upgraded Corvus Pharmaceuticals Inc (NASDAQ:CRVS) to Hold in a statement released on Thursday September 22, 2016.

Having a price of $15.57, Corvus Pharmaceuticals Inc (NASDAQ:CRVS) traded 3.94% higher on the day. With the last close up 12.34% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. CRVS has recorded a 50-day average of $14.32 and a two hundred day average of $13.86. Trade Volume was down over the average, with 15,177 shares of CRVS changing hands under the typical 28,956

Recent Performance Chart

Corvus Pharmaceuticals Inc (NASDAQ:CRVS)

Corvus Pharmaceuticals Inc has with a one year low of $9.63 and a one year high of $16.62 and has a market capitalization of $0.

A total of 1 analyst has released a report on Corvus Pharmaceuticals Inc. zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $24.00.

More About Corvus Pharmaceuticals Inc (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. It is engaged in developing drugs designed to reprogram T-cells to restore the immune balance needed for tumor destruction. It offers approximately four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. Its product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. It focuses on evaluating CPI-444 in a multicenter Phase I/IB clinical trial in patients with various solid tumors. It offers a humanized anti-CD73 monoclonal antibody. It is evaluating orally administered antagonists that are selective for A2B, an alternate adenosine receptor. It focuses on Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *